NCT07058103
- Conditions
- Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory
- Locations
-
- The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
Clinical trial condition
Angioimmunoblastic T-Cell Lymphoma Refractory
Explore clinical trials studying Angioimmunoblastic T-Cell Lymphoma Refractory. Study availability and eligibility vary by location and protocol.
2 public trials
1 recruiting study
Angioimmunoblastic T-Cell Lymphoma Refractory trial results
Completed
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
- Conditions
- ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
- Locations
-
- British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
- Peking University Third Hospital Beijing, Beijing Municipality, China
- Beijing Hospital Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital Beijing, Beijing Municipality, China
Related conditions
- Angioimmunoblastic T-Cell Lymphoma Recurrent (2)
- Adult Nasal Type Extranodal NK/T-cell Lymphoma (1)
- ALK-negative Anaplastic Large Cell Lymphoma (1)
- ALK-Positive Anaplastic Large Cell Lymphoma (1)
- Anaplastic Large Cell Lymphoma (1)
- Anaplastic Large Cell Lymphoma, ALK-negative (1)
- Anaplastic Large Cell Lymphoma, ALK-Positive (1)
- Angioimmunoblastic T-cell Lymphoma (1)